CStone Pharmaceuticals announced preliminary results from the phase Ia trial of the company's anti-CTLA-4 antibody in an oral presentation at the 22nd Annual Meeting of the Chinese Society of Clinical ...
CStone Pharmaceuticals, a leading biopharmaceutical company, and Jiangsu Hengrui Pharmaceuticals announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback